[go: up one dir, main page]

MXPA02009791A - El gen de alta masa osea de 11q13.3. - Google Patents

El gen de alta masa osea de 11q13.3.

Info

Publication number
MXPA02009791A
MXPA02009791A MXPA02009791A MXPA02009791A MXPA02009791A MX PA02009791 A MXPA02009791 A MX PA02009791A MX PA02009791 A MXPA02009791 A MX PA02009791A MX PA02009791 A MXPA02009791 A MX PA02009791A MX PA02009791 A MXPA02009791 A MX PA02009791A
Authority
MX
Mexico
Prior art keywords
methods
present
gene
bone mass
high bone
Prior art date
Application number
MXPA02009791A
Other languages
English (en)
Inventor
Randall D Little
Original Assignee
Genome Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/543,771 external-priority patent/US6780609B1/en
Priority claimed from US09/544,398 external-priority patent/US6770461B1/en
Application filed by Genome Therapeutics Corp filed Critical Genome Therapeutics Corp
Publication of MXPA02009791A publication Critical patent/MXPA02009791A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Pregnancy & Childbirth (AREA)

Abstract

La presente invencion se refiere a metodos y materiales utilizados para aislar y detectar un gen de alta masa osea y un gen de tipo silvestre correspondiente, y mutantes de los mismos. La presente invencion se refiere tambien al gen de alta masa osea, al gen de tipo silvestre correspondiente, y a mutantes de los mismos. Los genes identificados en la presente invencion participan en el desarrollo oseo y en la senalizacion de adhesion focal. La invencion ofrece tambien acidos nucleicos, incluyendo secuencias codificadoras, cebadores de oligonucleotidos y sondas, proteinas, vectores de clonacion, vectores de expresion, huespedes transformados, metodos para desarrollar composiciones farmaceuticas, metodos para identificar moleculas involucradas en el desarrollo oseo, y metodos pera diagnosticar y tratar enfermedades involucradas en el desarrollo oseo. En modalidades preferidas, la presente invencion se enfoca a metodos para tratar, diagnosticar y prevenir la osteoporosis.
MXPA02009791A 2000-04-05 2000-06-21 El gen de alta masa osea de 11q13.3. MXPA02009791A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/543,771 US6780609B1 (en) 1998-10-23 2000-04-05 High bone mass gene of 1.1q13.3
US09/544,398 US6770461B1 (en) 1998-10-23 2000-04-05 High bone mass gene of 11q13.3
PCT/US2000/016951 WO2001077327A1 (en) 2000-04-05 2000-06-21 THE HIGH BONE MASS GENE OF 11q13.3

Publications (1)

Publication Number Publication Date
MXPA02009791A true MXPA02009791A (es) 2004-09-06

Family

ID=27067425

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02009791A MXPA02009791A (es) 2000-04-05 2000-06-21 El gen de alta masa osea de 11q13.3.

Country Status (11)

Country Link
EP (1) EP1268775B1 (es)
JP (1) JP2004515209A (es)
CN (1) CN1454256A (es)
AR (1) AR028316A1 (es)
AU (2) AU5626900A (es)
BR (1) BR0017197A (es)
CA (1) CA2402410A1 (es)
IL (1) IL151904A0 (es)
MX (1) MXPA02009791A (es)
NZ (1) NZ521769A (es)
WO (1) WO2001077327A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555654B1 (en) 1997-04-15 2003-04-29 The Wellcome Trust Limited As Trustee For The Wellcome Trust LDL-receptor
US7244577B2 (en) 1997-04-15 2007-07-17 Merck & Co., Inc. Method of screening for modulator of LRP5 activity
AU733722B2 (en) 1997-04-15 2001-05-24 Merck Sharp & Dohme Corp. Novel LDL-receptor
JP2004507236A (ja) * 2000-08-18 2004-03-11 プロスケリア 骨粗鬆症の診断および治療に有用な調節遺伝子および系
EP1483288A4 (en) * 2001-05-11 2005-09-21 Genome Therapeutics Corp HBM VARIANTS MODULATING BONE MASS AND LIPID LEVELS
US7514594B2 (en) 2001-05-11 2009-04-07 Wyeth Transgenic animal model of bone mass modulation
AU2002342734B2 (en) * 2001-05-17 2007-07-26 Oscient Pharmaceuticals Corporation Reagents and methods for modulating Dkk-mediated interactions
AU2003292404A1 (en) * 2002-12-13 2004-07-09 Oxagen Limited Genetic susceptibility
WO2006004066A1 (ja) * 2004-07-02 2006-01-12 Locomogene, Inc. S1-5を含有するタンパク質製剤
JPWO2006004066A1 (ja) * 2004-07-02 2008-04-24 株式会社ロコモジェン Ｓ１−５を含有するタンパク質製剤
JP6745220B2 (ja) * 2013-09-16 2020-08-26 ツェーエムエム−フォルシュングスツェントルム フュア モレクラレ メディツィン ゲーエムベーハー 骨髄性悪性腫瘍の診断のための突然変異体カルレチクリン

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7392696A (en) * 1995-10-04 1997-04-28 Warner-Lambert Company Compounds, compositions and methods for inhibiting the binding of proteins containing an sh2 domain to cognate phosphorylated proteins
US5691153A (en) * 1996-09-06 1997-11-25 Creighton University Genetic markers to detect high bone mass
AU733722B2 (en) * 1997-04-15 2001-05-24 Merck Sharp & Dohme Corp. Novel LDL-receptor
BE1011331A6 (fr) * 1997-08-20 1999-07-06 Univ Catholique De Louvain Hal Polypeptide associe au peroxysome, sequence nucleotidique encodant ledit polypeptide et leur utilisation dans le diagnostic et/ou le traitement de maladies ou de lesions pulmonaires.
CA2319493A1 (en) * 1998-03-18 1999-09-23 Regine Bohacek Heterocyclic signal transduction inhibitors, compositions containing them
JP2002539843A (ja) * 1999-03-26 2002-11-26 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ５０個のヒト分泌タンパク質
CN100469792C (zh) * 2000-05-26 2009-03-18 奥赛恩特药品公司 通过Zmax1或HBM基因调节脂质水平
JP2004507236A (ja) * 2000-08-18 2004-03-11 プロスケリア 骨粗鬆症の診断および治療に有用な調節遺伝子および系

Also Published As

Publication number Publication date
NZ521769A (en) 2004-12-24
EP1268775A1 (en) 2003-01-02
EP1268775B1 (en) 2008-11-19
JP2004515209A (ja) 2004-05-27
AU2000256269A1 (en) 2002-01-10
CN1454256A (zh) 2003-11-05
WO2001077327A1 (en) 2001-10-18
IL151904A0 (en) 2003-04-10
CA2402410A1 (en) 2001-10-18
BR0017197A (pt) 2003-01-14
AR028316A1 (es) 2003-05-07
AU5626900A (en) 2001-10-23
AU2000256269B2 (en) 2006-11-02

Similar Documents

Publication Publication Date Title
MXPA03010077A (es) Abonadora de siembra a voleo con deflector movible.
WO2002092764A3 (en) Transgenic animal model of bone mass modulation
Garen Sense and Nonsense in the Genetic Code: Three exceptional triplets can serve as both chain-terminating signals and amino acid codons.
EA199900939A1 (ru) Остеопротегерин-связывающие белки и рецепторы
ATE378407T1 (de) Morphogene protein-spezifische zelloberflächenrezeptoren und ihre verwendungen
MXPA02009791A (es) El gen de alta masa osea de 11q13.3.
MX9708427A (es) Serpina derivada de pancreas.
CA2192940A1 (en) Nucleotide sequences of pestivirus strains, polypeptides encoded by these sequences and use thereof for diagnosis and prevention of pestivirus infections
DE69840333D1 (de) 2-m übergang des zellzyklus
ATE300619T1 (de) Humane checkpointkinase, hcds1, zusammensetzungen und verfahren
EE200100040A (et) Meetod raku fenotüüpi muutva modulaatori identifitseerimiseks ja valmistamiseks, sihtmärkbiomolekulide eraldamiseks ja/või samastamiseks ning meditsiinitoote arendamiseks ja valmistamiseks
ZA200207883B (en) The High Bone Mass Gene of 11Q13.3.
EA200000845A1 (ru) Ген, кодирующий новый маркер рака
ATE255638T1 (de) Nukleotidsequenzen und gegen cycloheximid resistente proteine
ZA200208977B (en) Regulating lipid levels via the zmaxi or hbm gene.
HUT77029A (hu) A GAP-protein SH3 doménjéhez kötődni képes peptidek, ezeket kódoló nukleotidszekvenciák és előállításuk és alkalmazásuk
WO1996029407A3 (en) Cellubrevin homologs
ATE483019T1 (de) Aus einem neuroblastom in stufe 4s isoliertenukleinsäuren
TW200502398A (en) Use of peptidylarginine deiminase type IV
Liu Molecular cloning and sequencing of a completecDNA coding for a mung bean seed albumin
MX9703970A (es) Quimiocinas expresadas, su produccion y usos.
TW200502395A (en) Method for evaluating an agent for improving beta cell dysfunction
MX9709747A (es) Serpina novedosa derivada de hipotalamo humano.
YU4101A (sh) Novi postupci za identifikovanje liganada i ciljnih biomolekula
WO2002090545A3 (fr) Acide nucleique codant le polypeptide cgl1 et application de cet acide nucleique et du polypeptide cgl1 au diagnostic et en therapeutique

Legal Events

Date Code Title Description
HC Change of company name or juridical status
FG Grant or registration